Phase II study of rituximab in the treatment of cladribine-failed patients (pts.) with hairy cell leukemia (HCL).

被引：0
|
作者：
Nieva, J
Bethel, K
Baker, T
Saven, A
机构：
[1] Scripps Res Inst, Dept Pathol, La Jolla, CA USA
[2] Scripps Canc Ctr, La Jolla, CA USA
[3] Cecil H & Ida M Green Canc Ctr, La Jolla, CA USA
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1535
引用
收藏
页码：364A / 365A
页数：2
相关论文
共 50 条
  • [31] Complete molecular remission induced by concomitant Cladribine - Rituximab treatment in a case of multi-resistant Hairy Cell Leukemia
    Forconi, Francesco
    Toraldo, Francesca
    Sozzi, Elisa
    Amato, Teresa
    Raspadori, Donatella
    Lauria, Francesco
    LEUKEMIA & LYMPHOMA, 2007, 48 (12) : 2441 - 2443
  • [32] Cladribine (2CDA) followed by 8 weeks of rituximab can eradicate minimal residual disease (MRD) in hairy cell leukemia (HCL)
    Ravandi, F
    Kantarjian, H
    Verstovsek, S
    Koller, C
    Faderl, S
    Ferrajoli, A
    Thomas, D
    Jones, D
    Bueso-Ramos, C
    Jorgensen, J
    Keating, M
    O'Brien, S
    ANNALS OF ONCOLOGY, 2005, 16 : 157 - 158
  • [33] First-Line Treatment of Hairy Cell Leukemia with Cladribine Followed by Rituximab Consolidation Significantly Improves Leukemia-Free Survival
    Amhez, Ghid
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S227 - S228
  • [34] First-Line Treatment of Hairy Cell Leukemia with Cladribine Followed by Rituximab Consolidation Significantly Improves Leukemia-Free Survival
    Amhaz, Ghid
    Ibrahim, Ali
    Usta, Ulfat
    El Cheikh, Jean
    Bazarbachi, Ali
    Abou Dalle, Iman
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (08): : 564 - 566
  • [35] Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia
    Montillo, M
    Tedeschi, A
    O'Brien, S
    Di Raimondo, F
    Lerner, S
    Ferrajoli, A
    Morra, E
    Keating, MJ
    CANCER, 2003, 97 (01) : 114 - 120
  • [36] Analysis of Parameters Predicting Treatment Efficacy and Outcome In Patients with Hairy Cell Leukemia (HCL) Receiving Subcutaneous Cladribine In the ICGHCL2004 Protocol (by the Italian Cooperative Group on HCL)
    Forconi, Francesco
    Cencini, Emanuele
    Zaja, Francesco
    Intermesoli, Tamara
    Fiore, Francesca
    Puccini, Benedetta
    Stelitano, Caterina
    Cantaffa, Renato
    Pulsoni, Alessandro
    Zaccaria, Alfonso
    Zinzani, Pier Luigi
    Piccin, Andrea
    Gherlinzoni, Filippo
    Levis, Alessandro
    Martinelli, Giovanni
    Barulli, Sara
    Morabito, Fortunato
    Pierri, Ivana
    Ruggeri, Miriana
    Caremani, Alessandra
    Masini, Luciano
    Polimeno, Giuseppe
    Guerrasio, Angelo
    Sozzi, Elisa
    Rossi, Davide
    Bertoni, Francesco
    Galieni, Piero
    Gobbi, Marco
    Cortelazzo, Sergio
    Rigacci, Luigi
    Gallamini, Andrea
    Foa, Robin
    Lauria, Francesco
    BLOOD, 2010, 116 (21) : 588 - 589
  • [37] A Single Arm Phase II Pilot Study of Low Dose Vemurafenib Plus Rituximab in the FrontLine and Relapsed/Refractory Treatment of Hairy Cell Leukemia
    Hermel, David Jacob
    Ter-Zakarian, Anna
    New, Jacob
    Saven, Alan
    BLOOD, 2023, 142
  • [38] Complete remission of hairy cell leukemia variant (HCL-v) complicated by red cell aplasia post treatment with rituximab
    Quach, Hang
    Januszewicz, Henry
    Westerman, David
    HAEMATOLOGICA, 2005, 90 : 72 - 73
  • [39] Hairy cell leukemia:: Clinical features and treatment with cladribine.: A retrospective review of 21 patients.
    De Boeck, K
    Zachée, P
    Paridaens, K
    De Bock, R
    BLOOD, 1998, 92 (10) : 235B - 235B
  • [40] Long-term follow-up of patients with hairy cell leukemia after cladribine treatment
    Saven, A
    Burian, C
    Koziol, JA
    Piro, LD
    BLOOD, 1998, 92 (06) : 1918 - 1926
12345